DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX tria…

Biotechnology

US, Minneapolis [HQ]

Analysts
Dividend Payments
Government Awards
Insiders
Lobbying Expenses
Segment Revenues
Shareholder Structure
Supply / Portfolio
Valuation Models [Soon]

Earnings Call Transcripts

Earnings Call · Transcripts · Speakers

This analysis tool shows transcript versions of the official earnings calls hosted by DiaMedica Therapeutics Inc.

Could not find a transcript

Earnings Call Transcripts

Could not find a transcript

Peer Group

Sorry! None of DMAC's peers has listed transcripts.

SEC Reader

The document search tool might be interesting as well.
Give it a try, to quickly access SEC Filings-

10-K · 10-Q · DEF 14A · S-4

Upcoming Transcript Tools

Full Text Search - Across All Transcripts
Detail Speaker Profiles
Non-US Transcripts